← Kailera Therapeutics, Inc. Common Stock overview

Kailera Therapeutics, Inc. Common Stock vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Kailera Therapeutics, Inc. Common Stock (KLRA)

Q3 2026
▲4

Kailera's oral GLP-1 succeeds; Pfizer takeover talk and capital access lift KLRA

  • Pfizer names Kailera as ideal acquisition target Pfizer's CEO said his company has a huge balance sheet and could buy Kailera to deepen its weight-loss pipeline. A takeover would likely come at a premium, and the interest validates Kailera's science. This directly raises the odds of a buyout and supports the stock price.

    A potential acquisition by a major pharma is a direct, big-picture reason KLRA could move higher.

  • Positive Phase 3 results for oral GLP-1 obesity/diabetes drug Kailera reported that its oral GLP-1 pill helped patients lose up to 11.1% of their weight by week 50 and lowered blood sugar in diabetes. No new safety issues appeared. Strong late-stage data for a lead asset makes future approval and sales more likely, pushing the stock up.

    This is the most important company-specific event: clinical success directly boosts the value of its main drug.

  • Kailera highlighted as a beaten-down GLP-1 buy After falling 23% since its April IPO, Kailera was named an attractive GLP-1 pipeline play. Its oral candidate hit 11.1% weight loss in a Phase 3 trial, and it is also developing dual and triple agonists. This bargain-hunting view can draw buyers and lift the shares.

    It explains why investors might see KLRA as undervalued despite recent price weakness, a key force behind a rebound.

  • Strong biopharma capital markets and partner Hengrui's growth Biopharma confidence hit a four-year high, IPOs surged, and Kailera's partner Hengrui reported innovative drug sales up 16.4% with positive Phase 3 results for the same oral GLP-1. A healthy funding environment and a strong partner make it easier for Kailera to raise money and advance its pipeline.

    It shows the broad financial and partner backdrop that supports KLRA's ability to fund and grow.

July 2026
▲4

Kailera's oral GLP-1 succeeds; Pfizer takeover talk and capital access lift KLRA

  • Pfizer names Kailera as ideal acquisition target Pfizer's CEO said his company has a huge balance sheet and could buy Kailera to deepen its weight-loss pipeline. A takeover would likely come at a premium, and the interest validates Kailera's science. This directly raises the odds of a buyout and supports the stock price.

    A potential acquisition by a major pharma is a direct, big-picture reason KLRA could move higher.

  • Positive Phase 3 results for oral GLP-1 obesity/diabetes drug Kailera reported that its oral GLP-1 pill helped patients lose up to 11.1% of their weight by week 50 and lowered blood sugar in diabetes. No new safety issues appeared. Strong late-stage data for a lead asset makes future approval and sales more likely, pushing the stock up.

    This is the most important company-specific event: clinical success directly boosts the value of its main drug.

  • Kailera highlighted as a beaten-down GLP-1 buy After falling 23% since its April IPO, Kailera was named an attractive GLP-1 pipeline play. Its oral candidate hit 11.1% weight loss in a Phase 3 trial, and it is also developing dual and triple agonists. This bargain-hunting view can draw buyers and lift the shares.

    It explains why investors might see KLRA as undervalued despite recent price weakness, a key force behind a rebound.

  • Strong biopharma capital markets and partner Hengrui's growth Biopharma confidence hit a four-year high, IPOs surged, and Kailera's partner Hengrui reported innovative drug sales up 16.4% with positive Phase 3 results for the same oral GLP-1. A healthy funding environment and a strong partner make it easier for Kailera to raise money and advance its pipeline.

    It shows the broad financial and partner backdrop that supports KLRA's ability to fund and grow.

Latest
▲4

Kailera's oral GLP-1 succeeds; Pfizer takeover talk and capital access lift KLRA

  • Pfizer names Kailera as ideal acquisition target Pfizer's CEO said his company has a huge balance sheet and could buy Kailera to deepen its weight-loss pipeline. A takeover would likely come at a premium, and the interest validates Kailera's science. This directly raises the odds of a buyout and supports the stock price.

    A potential acquisition by a major pharma is a direct, big-picture reason KLRA could move higher.

  • Positive Phase 3 results for oral GLP-1 obesity/diabetes drug Kailera reported that its oral GLP-1 pill helped patients lose up to 11.1% of their weight by week 50 and lowered blood sugar in diabetes. No new safety issues appeared. Strong late-stage data for a lead asset makes future approval and sales more likely, pushing the stock up.

    This is the most important company-specific event: clinical success directly boosts the value of its main drug.

  • Kailera highlighted as a beaten-down GLP-1 buy After falling 23% since its April IPO, Kailera was named an attractive GLP-1 pipeline play. Its oral candidate hit 11.1% weight loss in a Phase 3 trial, and it is also developing dual and triple agonists. This bargain-hunting view can draw buyers and lift the shares.

    It explains why investors might see KLRA as undervalued despite recent price weakness, a key force behind a rebound.

  • Strong biopharma capital markets and partner Hengrui's growth Biopharma confidence hit a four-year high, IPOs surged, and Kailera's partner Hengrui reported innovative drug sales up 16.4% with positive Phase 3 results for the same oral GLP-1. A healthy funding environment and a strong partner make it easier for Kailera to raise money and advance its pipeline.

    It shows the broad financial and partner backdrop that supports KLRA's ability to fund and grow.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

© 2026 MarketIVWhy